The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease
Background and Aims: The synthetic atypical cannabinoid Abn-CBD, a cannabidiol (CBD) derivative, has been recently shown to modulate the immune system in different organs, but its impact in obesity-related meta-inflammation remains unstudied. We investigated the effects of Abn-CBD on metabolic and i...
Main Authors: | Silvana Y. Romero-Zerbo, María García-Fernández, Vanesa Espinosa-Jiménez, Macarena Pozo-Morales, Alejandro Escamilla-Sánchez, Lourdes Sánchez-Salido, Estrella Lara, Nadia Cobo-Vuilleumier, Alex Rafacho, Gabriel Olveira, Gemma Rojo-Martínez, Benoit R. Gauthier, Isabel González-Mariscal, Francisco J. Bermúdez-Silva |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-03-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fendo.2020.00103/full |
Similar Items
-
Prevalence of non-alcoholic fatty liver disease in patients with prediabetes
by: Bhumi Agarwal, et al.
Published: (2021-03-01) -
Nonalcoholic fatty liver disease in prediabetes – Predisposing and protective factors
by: Jennifer Miranda, et al.
Published: (2021-01-01) -
Assessment of Chromium Levels in Patients with Prediabetes
by: Zahra Torabi, et al.
Published: (2014-04-01) -
Clinical Usefulness of Anthropometric Indices to Predict the Presence of Prediabetes. Data from the ILERVAS Cohort
by: Marta Sánchez, et al.
Published: (2021-03-01) -
Neck circumference to height ratio is a reliable predictor of liver stiffness and nonalcoholic fatty liver disease in prediabetes
by: Samim Ali Mondal, et al.
Published: (2018-01-01)